Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Growth in Short Interest

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 9,390,000 shares, an increase of 25.5% from the January 15th total of 7,480,000 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 6.6 days.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $7.79 on Friday. The business’s 50 day moving average price is $8.52 and its 200 day moving average price is $7.61. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC lifted its position in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Natixis acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth $49,000. Blue Trust Inc. increased its holdings in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $90,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.